BioSpace News Archive

BiomX Inc. (the “Company”) (NYSE: PHGE), a clinical-stage company developing both natural and engineered phage therapies that target specific pathogenic bacteria, today announced that the Company will host a conference call and live audio webcast on Thursday, May 14, 2020, at 8:00 a.m. ET to report first quarter 2020 financial results and provide a corporate update.

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a biopharmaceutical company focused on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases, today announced that the Compensation Committee of Mirum’s Board of Directors granted non-qualified stock option awards to purchase an aggregate of 17,500 shares of common stock to two new employees under Mirum’s 2020 Inducement Plan.

Merus N.V. (Nasdaq: MRUS) (“Merus”, the “Company,” “we”, or “our”), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and TriclonicsTM), today announced financial results for the first quarter that ended March 31, 2020, and provided a business update.

SeaSpine Holdings Corporation, a global medical technology company focused on surgical solutions for the treatment of spinal disorders, announced the Company will participate in a virtual fireside chat with BTIG.

In an era of heightened awareness over viruses and contaminants, Advancing Medical Innovations (AMI) announced its client Performance Compounds Inside (PCI)'s novel 3PRE Technology can bring unprecedented antimicrobial protection to products within the healthcare industry – with little or no disruption to current manufacturing processes.

Quest Diagnostics Incorporated (NYSE: DGX), the world’s leading provider of diagnostic information services, announced today the pricing of a public offering of $550 million aggregate principal amount of its 2.800% senior notes due 2031 under Quest Diagnostics’ shelf registration statement

The U.S. Food and Drug Administration continued to take action in the ongoing response effort to the COVID-19 pandemic

AtriCure, Inc., a leading innovator in treatments for atrial fibrillation and left atrial appendage management, announced the pricing of its underwritten offering of 3,977,273 shares of its common stock at a price to the public of $44.00 per share pursuant to its existing automatic shelf registration statement.

AbVision, Inc., an innovative biopharmaceutical company, announced today that the Company has developed a novel first-in-class COVID-19 vaccine candidate (AVI-205) with an active targeting feature, powered by its ImmunoBuster-IITM Active Targeting Vaccine Platform.